Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals Stock
A loss of -1.660% shows a downward development for Biocryst Pharmaceuticals.
Biocryst Pharmaceuticals is currently one of the favorites of our community with 19 Buy predictions and no Sell predictions.
With a target price of 14 € there is a hugely positive potential of 93.16% for Biocryst Pharmaceuticals compared to the current price of 7.25 €.
So far the community has only identified positive things for Biocryst Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
S********** s********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | -1.660% | 14.228% | 31.139% | -11.269% | 12.416% | -11.588% | -24.146% |
| Heron Therapeutics Inc. | -0.780% | 0.690% | -13.021% | -56.987% | -8.259% | -53.119% | -93.017% |
| Evolus Inc | -2.170% | -2.747% | -14.078% | -72.977% | -35.046% | -57.091% | -66.477% |
| Sangamo Therapeutics Inc. | -2.330% | 10.544% | -23.168% | -62.173% | 5.803% | -86.723% | -96.148% |
Comments
BioCryst Pharmaceuticals (NASDAQ:BCRX) is now covered by analysts at Evercore Inc. They set an "outperform" rating and a $17.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat